Taken together, comparing clinical characteristics and comprehensive genomic landscapes via whole exome sequencing (WES) in diverse EGFR TKI responders; de novo resistance, intermediate and long-term responses, EGFR mutation NSCLC will enable the identification of potential mechanisms that confer resistance to EGFR TKI treatment. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.